CRISPR Therapeutics AG (CRSP) closed at $48.05 in the latest trading session, marking a +0.47% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%. The the stock of company has risen by 0.18% in the past month, leading the Medical sector's loss of 3.35% and undershooting the S&P 500's gain of 4.31%. The investment community will be closely monitoring the pe ...

文章核心观点 - CRISPR Therapeutics和Moderna是两家创新型生物科技公司,但今年股价表现不佳 [1] - CRISPR Therapeutics获批首个基因编辑疗法Casgevy,但短期内难以为公司带来显著财务贡献 [2][3] - Moderna虽然新冠疫苗销售下滑,但正在开发多款新产品,有望长期表现良好 [5][6] CRISPR Therapeutics - CRISPR Therapeutics获批首个基因编辑疗法Casgevy,这是使用CRISPR技术的首个上市药物 [2] - Casgevy的适应症包括镰状细胞病和输血依赖性β地中海贫血,目标市场约35,000名患者 [3] - Casgevy价格高达220万美元,但由于需要复杂的制造和给药过程,短期内难以为公司带来大量收入 [3] - 尽管存在这些因素,但Casgevy的长期前景仍然看好,公司有望成为基因编辑领域的主要参与者 [4] Moderna - Moderna在疫情期间凭借新冠疫苗获得成功,但疫苗销售已大幅下滑 [5] - 公司获批新的RSV疫苗mRESVIA,并有望在未来2年内推出更多新产品 [5] - Moderna正在开发多款新产品,包括综合新冠/流感疫苗、独立流感疫苗、巨细胞病毒疫苗等 [5][6] - 尽管目前财务业绩不佳,但Moderna丰富的mRNA产品管线有望带来未来增长动力 [6][7]

CRISPR Therapeutics is trading around multiyear lows. Finding an undervalued growth stock can lead to some oversize returns in the long run. In some cases, it can be as simple as focusing on sectors of the market that might not be getting much attention of late, and thus could make for attractive under-the-radar investments right now. One stock that has been struggling and that arguably should be doing a lot better these days is CRISPR Therapeutics (CRSP 1.05%). There was a lot of excitement around the heal ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $45.71, demonstrating a +0.29% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Coming into today, shares of the company had gained 0.13% in the past month. In that same time, the Medical sector lost 3.6%, while the S&P 500 gained 1.21%. Analysts and investors alike will be ke ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. It's not fun missing out when a hot stock goes wild. The viral popularity of injectable diabetes and weight loss drugs, called GLP-1s, propelled pharmaceutical stock Novo Nordisk to over 350% in returns over the past five years. That sizeable return beat the broader market by a comfortable margin. But you needn't worry if you feel that you've missed out. The great thing about investing is th ...

Bargain hunters should love these great stocks. By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found. Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (CRSP -2.65%), Gilead Sciences (GILD 0.05%), and Pfizer (PFE -0.81%). You can still get in on the ground floor Prosper Junior Bakiny (CRISPR Therapeutics): Valuing relatively small biotech compani ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%. The the stock of company has fallen by 0.8% in the past month, lagging the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%. Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming ea ...

There's a lot of growth on the way, and soon. CRISPR Therapeutics' (CRSP -0.56%) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out. Still, investing in biotech companies isn't for the faint of heart, and even a s ...

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. In the past three years, CRISPR Therapeutics (CRSP -0.33%) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in multiple countries. However, this regulatory milestone hasn't been accompanied by a strong stock market performance. CRISPR Therapeutics has significantly lagged the market since 2021. What is going on with this gene-editing ...